Loading...
•
Dec 31, 2019
MannKind Q4 2019 Earnings Report
MannKind reported Q4 2019 earnings, showing revenue growth driven by Afrezza sales and progress in collaborations.
Key Takeaways
MannKind Corporation's Q4 2019 total revenues reached $16.0 million, with Afrezza net revenue at $7.8 million, a 35% increase compared to Q4 2018. The company's net loss for the quarter was $14.3 million, or $0.07 per share. The collaboration with United Therapeutics on TreT continues to make progress.
Total revenue for Q4 2019 was $16.0 million.
Afrezza net revenue for Q4 2019 increased by 35% to $7.8 million compared to Q4 2018.
Collaborations and services revenue for Q4 2019 decreased by 20% to $8.2 million compared to Q4 2018.
Net loss for Q4 2019 was $14.3 million, or $0.07 per share.
Revenue by Segment
Forward Guidance
MannKind is working with United Therapeutics on TreT and expects to file with the FDA within 12 months.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...